Myriad Genetics Focuses on Expanding Access, Collaboration and Equity in Genetic Testing at National Society of Genetic Counselors Meeting
Myriad Genetics, Inc. SALT LAKE CITY, Nov. 14, 2022 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will highlight efforts to expand access to genetic knowledge of prenatal and hereditary cancer at the 41st Annual meeting of the National Society of Genetic Counselors (NSGC), November 16-19 in …